Cyclooxygenase-2 polymorphisms and susceptibility to gastric carcinoma: A meta-analysis

World Journal of Gastroenterology

Volumn 16, Issue 43, 2010, Pages 5510-5517

  Liu, Jia Li ^a   Liang, Yuan ^a   Wang, Zhen Ning ^a   Zhou, Xin ^a   Xing, Li Li ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cyclooxygenases 2; Gastric cancer; Meta analysis; Polymorphisms; Susceptibility

Indexed keywords

CYCLOOXYGENASE 2;

ALLELE; ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER RISK; CONFIDENCE INTERVAL; EMBASE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MEDLINE; STOMACH CARCINOMA;

EID: 78649694233     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i43.5510     Document Type: Article

References (38)

1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-362.
2. Parkin DM.International variation.Oncogene 2004;23:329-6340
3. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
5. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
6. Marx J. Cancer research. Inflammation and cancer: the link grows stronger. Science 2004; 306: 966-968.
7. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and phar- macogenetics. Nat Rev Cancer 2006; 6: 130-140
8. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 2S-8S; discussion 21S-22
9. Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biol 2004; 5: 241
10. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1073
11. Bakhle YS. COX-2 and cancer: a new approach to an old problem. Br J Pharmacol 2001; 134: 1137-1150
12. Yu LZ, Gao HJ, Bai JF, Sun G, Zhao HL, Sun L, Miu K, Zhao ZQ. Expression of COX-2 proteins in gastric mucosal lesions. World J Gastroenterol 2004; 10: 292-294
13. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000; 60: 5767-5772
14. Nithipatikom K, Isbell MA, Lindholm PF, Kajdacsy-Balla A, Kaul S, Campell WB. Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metastasis 2002; 19: 593-601
15. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716
16. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol 2006; 12: 1336-1345
17. Dixon DA. Regulation of COX-2 expression in human can- cers. Prog Exp Tumor Res 2003; 37: 52-71
18. Sitarz R, Leguit RJ, de Leng WW, Polak M, Morsink FM, Bak- ker O, Maciejewski R, Offerhaus GJ, Milne AN. The COX-2 promoter polymorphism -765 G>C is associated with ear- ly-onset, conventional and stump gastric cancers. Mod Pathol 2008; 21: 685-690
19. Attia J, Thakkinstian A, D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epide- miology. J Clin Epidemiol 2003; 56: 297-303
20. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epi- demiology (STROBE): explanation and elaboration. Epidemi- ology 2007; 18: 805-835
21. Pereira C, Medeiros RM, Dinis-Ribeiro MJ. Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available? Eur J Gastroenterol Hepatol 2009; 21: 76-91
22. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2 [updated September 2009]. Available from: URL: http://www.cochrane-handbook.org
23. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005; 28: 123-137.
24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558
25. Pereira C, Sousa H, Ferreira P, Fragoso M, Moreira-Dias L, Lopes C, Medeiros R, Dinis-Ribeiro M. -765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal meta-plasia. World J Gastroenterol 2006; 12: 5473-5478
26. Hou L, Grillo P, Zhu ZZ, Lissowska J, Yeager M, Zatonski W, Zhu G, Baccarelli A, Chanock SJ, Fraumeni JF Jr, Chow WH. COX1 and COX2 polymorphisms and gastric cancer risk in a Polish population. Anticancer Res 2007; 27: 4243-4247.
27. Liu F, Pan K, Zhang X, Zhang Y, Zhang L, Ma J, Dong C, Shen L, Li J, Deng D, Lin D, You W. Genetic variants in cy- clooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology 2006; 130: 1975-1984
28. Zhang XM, Miao XP, Tan W, Sun T, Guo YL, Zhao D, Lin DX. [Genetic polymorphisms in the promoter region of cyclooxygenase-2 and their association with risk of gastric cancer] Zhongguo Yixue Kexueyuan Xuebao 2006; 28: 119-123.
29. Jiang GJ, Wang HM, Zhou Y, Tan YF, Ding WL, Gao J, Ke Q, Wang Y, Shen J, Xu YC, Shen HB. The correlation study between the nucleotide polymorphisms of cyclooxygenase-2 gene and the susceptibility to gastric cancer. Nanjing Yike Daxue Xuebao 2007; 27: 890-894
30. Zhu KX, Li YM, Li X, Shi B, Zhou WC, Shan Y, Liu T, He WT, Feng TL. Association of COX-2 genetic polymorphisms and H pylori infection with gastric cancer in high-incidence Hexi area of Gansu Province in China. Shijie Huaren Xiaohua Zazhi 2008; 16: 2364-2370
31. Tang XF, Li YM, Li SX, Li X, He WT, Zhang D, Zhang QB, Zhu KH. Correlation between the nucleotide polymorphisms of COX-2 and the susceptibility to gastric cancer in Hui ethnic group. Shijie Huaren Xiaohua Zazhi 2009; 17: 1772-1776.
32. Canzian F, Franceschi S, Plummer M, van Doorn LJ, Lu Y, Gioia-Patricola L, Vivas J, Lopez G, Severson RK, Schwartz AG, Muñoz N, Kato I. Genetic polymorphisms in mediators of inflammation and gastric precancerous lesions. Eur J Can- cer Prev 2008; 17: 178-183
33. Saxena A, Prasad KN, Ghoshal UC, Bhagat MR, Krishnani N, Husain N. Polymorphism of -765G > C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection: a study from northern India. World J Gastroenterol 2008; 14: 1498-1503
34. Wang D, Mann JR, DuBois RN. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroen- terology 2005; 128: 1445-1461
35. Li HX, Chang XM, Song ZJ, He SX. Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma. World J Gastroenterol 2003; 9: 674-677.
36. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem 2000; 7: 1163-1170.
37. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000; 1470: M69-M78.
38. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-1280.